Literature DB >> 33629022

Reverse takotsubo cardiomyopathy caused by patent foramen ovale-related cryptogenic stroke: a case report.

Hiroya Takafuji1, Junya Arai1, Kuniyasu Saigusa2, Kotaro Obunai1.   

Abstract

BACKGROUND: Reverse takotsubo cardiomyopathy (rTTC) is recognized as an atypical type of TTC. It has been suggested that neurological events are typical trigger of rTTC, especially in young individuals. CASE
SUMMARY: In this case report, we describe a 16-year-girl who presented with neurological deficits due to embolic stroke and acute heart failure. Transthoracic echocardiography on admission revealed a severely reduced left ventricular (LV) function with akinesis of basal to mid LV, but normal contraction in apex. Coronary computed tomography angiography confirmed unobstructed coronary arteries. Two weeks later, her LV wall motion and ejection fraction were completely normalized. Transthoracic echocardiography and transoesophageal echocardiography demonstrated no evidence of intracardiac thrombus but showed a patent foramen ovale (PFO) with large shunt. After thorough work-up and brain-heart team discussion, we concluded that the patient developed rTTC due to cryptogenic stroke related with her PFO. She underwent percutaneous PFO closure for secondary prevention with good clinical course. DISCUSSION: Reverse TTC is a rare condition. It should be considered in stroke patients with acute heart failure. Quick diagnosis and management with brain-heart team is crucial for better prognosis.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Case report; Cryptogenic stroke; Patent foramen ovale; Percutaneous PFO closure; Reverse takotsubo cardiomyopathy

Year:  2020        PMID: 33629022      PMCID: PMC7891282          DOI: 10.1093/ehjcr/ytaa407

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Acute heart failure due to reverse takotsubo cardiomyopathy could be a critical cardiac manifestation in young patients presenting with a neurological event. Patent foramen ovale-related cryptogenic stroke is one of the major causes of the stroke in this population. Thorough work-up and discussion with brain–heart team is important for the appropriate management in these complicated cases.

Introduction

An atypical type of takotsubo cardiomyopathy (TTC) is described as a condition that does not have a confirmed typical appearance of ‘apical ballooning’ observed in TTC. It is generally referred to as ‘reverse TTC (rTTC)’ or ‘inverted TTC’. The clinical setting and disease course are different from those of the typical TTC., Previous reports demonstrated that physical stress, such as cerebrovascular disease, is the major trigger of rTTC compared with typical TTC, which is more likely to be triggered by emotional stress. A patent foramen ovale (PFO) is an important cause for cryptogenic stroke, especially in younger patients. Recently, it has been demonstrated that percutaneous PFO closure is superior over antithrombotic therapy alone in patients with PFO-related cryptogenic stroke. Here, we report a very rare case of rTTC caused by PFO-related cryptogenic stroke in a young girl, who underwent successful percutaneous PFO closure. Transferred to rehabilitation hospital. Final diagnosis of rTTC triggered by the cryptogenic stroke was made. 13 months (6 months after PFO closure)

Case presentation

A 16-year-old girl was transferred to the emergency room (ER) by ambulance due to dizziness, hemiplegia, and dyspnoea. She only had a remote history of asthma and denied any stressful events until the sudden onset of her symptoms. On admission, she had decreased level of consciousness with Glasgow Coma Scale of E2V2M5. She was afebrile and her vital signs showed an elevated blood pressure of 160/104 mmHg with pulse rate of 109 b.p.m. Physical examination revealed coarse crackles without heart murmur. Her oxygen saturation was 80% on room air, and a chest X-ray showed bilateral pulmonary oedema. She was intubated in ER due to respiratory failure. An urgent magnetic resonance image of the brain was organized which showed cerebral infarction in the right cerebellar hemisphere due to obstruction of the right vertebral artery (Figure and B) without evidence of haemorrhage. An emergency cerebral angiogram confirmed a right vertebral artery occlusion with thrombus, there was no evidence of dissection (Figure ). She was admitted to the intensive care unit, where she was treated medically with unfractionated heparin, warfarin, and enalapril 2.5 mg daily. Electrocardiogram (ECG) showed sinus rhythm with non-significant ST depression in inferior leads and T-wave inversion in lead aVL (Figure ). Troponin I was elevated at 1.531 ng/mL (normal <0.034 ng/mL). Bedside transthoracic echocardiography revealed severely reduced left ventricular (LV) function (LV ejection fraction 22%) and akinesis of the basal and mid LV with apical sparing (Figure : systolic phase; Figure : diastolic phase; see Video 1). The right ventricular function was preserved without dilatation. There was no LV thrombus nor pericardial effusion. Coronary computed tomography angiography showed no evidence of occlusion or dissection. Based on these findings, we tentatively diagnosed her cardiac condition as rTTC caused by the acute neurologic event. Follow-up echocardiography on Day 14 showed that her LV function had completely normalized (Video 2) with ECG normalized as well. Thorough work-up was conducted to identify the underlying cause of her embolic stroke. Cardiac monitoring and Holter ECG showed no significant atrial arrhythmia, such as atrial fibrillation. She did not take any oral contraceptives. Laboratory tests showed no evidence of hypercoagulable state; Protein S, Protein C, antithrombin III, antinuclear antibody, anti-cardiolipin antibody, and lupus anticoagulant were within normal range. No deep vein thrombosis was detected by venous ultrasonography in her lower extremities. A contrast-enhanced computed tomography did not reveal the presence of a tumour or a pulmonary arteriovenous fistula. Further work-up for connective tissue disorder and pheochromocytoma were all negative. Transthoracic echocardiography with bubble study showed a large right-to-left shunt (more than 30 bubbles) without Valsalva manoeuvre (Figure ; see Video 3). Transoesophageal echocardiography (TOE) showed no evidence of intracardiac thrombus but revealed shunt flow through a PFO at rest (Figure ). The bubble study confirmed the right-to-left shunt through the PFO with Valsalva manoeuvre (Figure ). (A) Diffusion-weighted magnetic resonance image showing cerebral infarction in right cerebellar hemisphere. (B) Magnetic resonance angiography showing the absence of the right vertebral artery (red arrow). (C) Cerebral angiography showing a right vertebral artery occlusion with thrombus (red arrowhead). Electrocardiogram showing sinus rhythm with non-significant ST depression in inferior leads and T-wave inversion in lead aVL. Transthoracic echocardiography in two-chamber view showing severe akinesis of the basal and mid segments with apical sparing. (A) Systolic phase. (B) Diastolic phase. Transthoracic echocardiography in four-chamber view, using agitated saline contrast microbubbles without Valsalva manoeuvre, showing significant right-to-left shunting. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (A) Transoesophageal echocardiography with colour Doppler showing shunt flow through a patent foramen ovale. (B) Transoesophageal echocardiography with bubble study confirming the passage of microbubbles from the right atrium to the left atrium through a patent foramen ovale with Valsalva manoeuvre (red circle). LA, left atrium; RA, right atrium; RV, right ventricle. Based on these test results and hospital course, the final diagnosis of rTTC triggered by the PFO-related cryptogenic stroke was made. On the hospital Day 34, she was transferred to the rehabilitation facility on long-term anticoagulation therapy with warfarin (target international normalized ratio 2.0–3.0). Two months after, transfer to a rehabilitation facility from our hospital, she was discharged to her home with mild neurological deficit of hand dexterity. During the outpatient follow-up, our brain–heart team, including neuro surgeons, interventional cardiologists, and cardiologists specializing in echocardiography, discussed consideration of the percutaneous PFO closure and concluded that the benefits of the device treatment would outweigh the risks because of high chance of stroke recurrence in this case. Seven months after onset of the stroke, she underwent percutaneous PFO closure for secondary prevention of a cerebrovascular event. A 25 mm Amplatzer PFO Occluder (Abbott, Chicago, IL, USA) was deployed under TOE guidance. After deployment, TOE showed no residual shunt through the PFO. There were no procedural complications, and no recurrent adverse events at 6 months follow-up after procedure.

Discussion

This is a very rare case of PFO-related cryptogenic stroke resulting in rTTC in a teenage girl. Neurological disorders especially stroke and subarachnoid haemorrhage have been linked with the trigger of TTC, and the role of the brain–heart axis in the pathogenesis of the TTC has been reported. TTC is part of a broad spectrum of cardiac alterations that may occur during the first few days after occurrence of acute brain disease. Previous study demonstrated that TTC occurs secondary to stroke in ∼1% of patients. The rTTC, an atypical type of TTC, occurs in ∼2.2% of all TTC cases. It is frequently associated with a cerebrovascular event and occurs in the younger population, compared with the classical type of TTC. The higher frequency of adrenoreceptors in the basal left ventricular wall (compared to the apical segment) in this age bracket is thought to be one of the main reasons for the higher prevalence of rTTC in younger individuals. Patent foramen ovale-related stroke is rare condition, but it has been suggested that this condition may be a more important contributor to strokes in younger patients. The data evaluating the role of PFO closure for recurrent stroke prevention in adolescent and young adults is limited. Previous studies indicate that existence of atrial septal aneurysm, large shunt, and/or shunt flow at rest through a PFO as a predictor of the recurrent stroke. Therefore, we considered that PFO closure would be beneficial in long-term management of this teenage patient. Appropriate patient selection for PFO closure through a comprehensive stroke workup with brain–heart team is crucial in order to offer the procedure to the patients who will benefit the most and avoid unnecessary procedures especially in the younger patient (age < 18 years old). In conclusion, we experienced a case of rTTC in the context of a cryptogenic stroke secondary to a PFO, and percutaneous PFO closure was performed successfully. Further investigation is needed to confirm the incidence and mechanism of this rare condition.

Lead author biography

Hiroya Takafuji, MD, is a chief physician of cardiology at Tokyo Bay Urayasu Ichikawa Medical Center in Japan. He was training structural heart disease interventions from April 2016 to June 2019 at Tokushima Red Cross Hospital in Japan (under Dr Hosokawa S., Dr Ogura R., and Dr Izumi T.). His specialization is structural heart disease interventions, especially, congenital heart disease such as atrial septal defect and PFO.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. Consent: The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: none declared. Click here for additional data file.
TimeEvent
Day 1Admitted to intensive care unit in our hospital for stroke with acute heart failure. Transthoracic echocardiography revealed a severe akinesis of the basal and mid segments with apical sparing. Electrocardiogram showed sinus rhythm with non-significant ST depression in inferior leads and T-wave inversion in lead aVL. Reverse takotsubo cardiomyopathy (rTTC) was suspected.
Day 8Transferred from intensive care unit to the neurology ward.
Day 14Echocardiography showed that her left ventricular function was completely normalized.
Day 17Transthoracic echocardiography and transoesophageal echocardiography revealed a shunt through the patent foramen ovale (PFO).
Day 25A contrast-enhanced computed tomography did not reveal the presence of a tumour or a pulmonary arteriovenous fistula.
Day 34

Transferred to rehabilitation hospital.

Final diagnosis of rTTC triggered by the cryptogenic stroke was made.

7 monthsPercutaneous PFO closure performed.

13 months (6 months after PFO closure)

No recurrent adverse events.
  15 in total

1.  Differences in the Clinical Profile and Outcomes of Typical and Atypical Takotsubo Syndrome: Data From the International Takotsubo Registry.

Authors:  Jelena R Ghadri; Victoria L Cammann; L Christian Napp; Stjepan Jurisic; Johanna Diekmann; Dana Roxana Bataiosu; Burkhardt Seifert; Milosz Jaguszewski; Annahita Sarcon; Catharina A Neumann; Verena Geyer; Abhiram Prasad; Jeroen J Bax; Frank Ruschitzka; Thomas F Lüscher; Christian Templin
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

Review 2.  Stroke-heart syndrome: clinical presentation and underlying mechanisms.

Authors:  Jan F Scheitz; Christian H Nolte; Wolfram Doehner; Vladimir Hachinski; Matthias Endres
Journal:  Lancet Neurol       Date:  2018-10-26       Impact factor: 44.182

Review 3.  PFO: Button me up, but wait … Comprehensive evaluation of the patient.

Authors:  Fausto Pizzino; Bijoy Khandheria; Scipione Carerj; Giuseppe Oreto; Maurizio Cusmà-Piccione; Maria Chiara Todaro; Lilia Oreto; Giampiero Vizzari; Gianluca Di Bella; Concetta Zito
Journal:  J Cardiol       Date:  2016-02-23       Impact factor: 3.159

Review 4.  SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

Authors:  Eric Horlick; Clifford J Kavinsky; Zahid Amin; Konstantinos Dean Boudoulas; John D Carroll; Ziyad M Hijazi; Dana Leifer; Helmi L Lutsep; John F Rhodes; Jonathan M Tobis
Journal:  Catheter Cardiovasc Interv       Date:  2019-03-21       Impact factor: 2.692

5.  Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.

Authors:  Lars Søndergaard; Scott E Kasner; John F Rhodes; Grethe Andersen; Helle K Iversen; Jens E Nielsen-Kudsk; Magnus Settergren; Christina Sjöstrand; Risto O Roine; David Hildick-Smith; J David Spence; Lars Thomassen
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

6.  Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy.

Authors:  Christian Templin; Jelena R Ghadri; Johanna Diekmann; L Christian Napp; Dana R Bataiosu; Milosz Jaguszewski; Victoria L Cammann; Annahita Sarcon; Verena Geyer; Catharina A Neumann; Burkhardt Seifert; Jens Hellermann; Moritz Schwyzer; Katharina Eisenhardt; Josef Jenewein; Jennifer Franke; Hugo A Katus; Christof Burgdorf; Heribert Schunkert; Christian Moeller; Holger Thiele; Johann Bauersachs; Carsten Tschöpe; Heinz-Peter Schultheiss; Charles A Laney; Lawrence Rajan; Guido Michels; Roman Pfister; Christian Ukena; Michael Böhm; Raimund Erbel; Alessandro Cuneo; Karl-Heinz Kuck; Claudius Jacobshagen; Gerd Hasenfuss; Mahir Karakas; Wolfgang Koenig; Wolfgang Rottbauer; Samir M Said; Ruediger C Braun-Dullaeus; Florim Cuculi; Adrian Banning; Thomas A Fischer; Tuija Vasankari; K E Juhani Airaksinen; Marcin Fijalkowski; Andrzej Rynkiewicz; Maciej Pawlak; Grzegorz Opolski; Rafal Dworakowski; Philip MacCarthy; Christoph Kaiser; Stefan Osswald; Leonarda Galiuto; Filippo Crea; Wolfgang Dichtl; Wolfgang M Franz; Klaus Empen; Stephan B Felix; Clément Delmas; Olivier Lairez; Paul Erne; Jeroen J Bax; Ian Ford; Frank Ruschitzka; Abhiram Prasad; Thomas F Lüscher
Journal:  N Engl J Med       Date:  2015-09-03       Impact factor: 91.245

7.  Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Anthony K Akobeng; Ibtihal Abdelgadir; Younes Boudjemline; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2018-03-30       Impact factor: 2.692

8.  Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology.

Authors:  Steven R Messé; Gary S Gronseth; David M Kent; Jorge R Kizer; Shunichi Homma; Lee Rosterman; John D Carroll; Koto Ishida; Navdeep Sangha; Scott E Kasner
Journal:  Neurology       Date:  2020-04-29       Impact factor: 11.800

9.  International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.

Authors:  Jelena-Rima Ghadri; Ilan Shor Wittstein; Abhiram Prasad; Scott Sharkey; Keigo Dote; Yoshihiro John Akashi; Victoria Lucia Cammann; Filippo Crea; Leonarda Galiuto; Walter Desmet; Tetsuro Yoshida; Roberto Manfredini; Ingo Eitel; Masami Kosuge; Holger M Nef; Abhishek Deshmukh; Amir Lerman; Eduardo Bossone; Rodolfo Citro; Takashi Ueyama; Domenico Corrado; Satoshi Kurisu; Frank Ruschitzka; David Winchester; Alexander R Lyon; Elmir Omerovic; Jeroen J Bax; Patrick Meimoun; Guiseppe Tarantini; Charanjit Rihal; Shams Y-Hassan; Federico Migliore; John D Horowitz; Hiroaki Shimokawa; Thomas Felix Lüscher; Christian Templin
Journal:  Eur Heart J       Date:  2018-06-07       Impact factor: 29.983

10.  Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.

Authors:  Guillaume Turc; David Calvet; Patrice Guérin; Marjorie Sroussi; Gilles Chatellier; Jean-Louis Mas
Journal:  J Am Heart Assoc       Date:  2018-06-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.